HUP0401854A2 - COX-2 inhibitorokat és aszpirint tartalmazó kombinációk - Google Patents
COX-2 inhibitorokat és aszpirint tartalmazó kombinációkInfo
- Publication number
- HUP0401854A2 HUP0401854A2 HU0401854A HUP0401854A HUP0401854A2 HU P0401854 A2 HUP0401854 A2 HU P0401854A2 HU 0401854 A HU0401854 A HU 0401854A HU P0401854 A HUP0401854 A HU P0401854A HU P0401854 A2 HUP0401854 A2 HU P0401854A2
- Authority
- HU
- Hungary
- Prior art keywords
- cox
- aspirin
- inhibitors
- combinations
- mammals
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001138 acetylsalicylic acid Drugs 0.000 title abstract 2
- 229940111134 coxibs Drugs 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány gyógyszerészeti összetételt biztosít emlősök COX-2gátlásra érzékeny állapotainak kezeléséhez, mely kombinációban a COX-2inhibitor és alacsony dózisú aszpirin hatásos mennyiségének szimultán,egymás utáni és külön-külön használatát foglalja magában. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0124459.9A GB0124459D0 (en) | 2001-10-11 | 2001-10-11 | Organic compounds |
PCT/EP2002/011380 WO2003033001A1 (en) | 2001-10-11 | 2002-10-10 | Combinations comprising cox-2 inhibitors and aspirin |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0401854A2 true HUP0401854A2 (hu) | 2004-12-28 |
Family
ID=9923664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401854A HUP0401854A2 (hu) | 2001-10-11 | 2002-10-10 | COX-2 inhibitorokat és aszpirint tartalmazó kombinációk |
Country Status (19)
Country | Link |
---|---|
US (2) | US20040235802A1 (hu) |
EP (1) | EP1435968A1 (hu) |
JP (1) | JP2005505606A (hu) |
KR (1) | KR20040044891A (hu) |
CN (1) | CN1625405A (hu) |
AU (1) | AU2006249254A1 (hu) |
BR (1) | BR0213181A (hu) |
CA (1) | CA2458981A1 (hu) |
CO (1) | CO5570661A2 (hu) |
GB (1) | GB0124459D0 (hu) |
HU (1) | HUP0401854A2 (hu) |
IL (1) | IL160620A0 (hu) |
MX (1) | MXPA04003365A (hu) |
NO (1) | NO20041432L (hu) |
NZ (1) | NZ532158A (hu) |
PL (1) | PL369005A1 (hu) |
RU (1) | RU2004114560A (hu) |
WO (1) | WO2003033001A1 (hu) |
ZA (1) | ZA200401302B (hu) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US7338971B2 (en) * | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
EP1492511B3 (fr) | 2002-04-09 | 2012-05-02 | Flamel Technologies | Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s) |
US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
EP1711454A4 (en) * | 2004-01-27 | 2007-04-04 | Merck Frosst Company | COMBINATION THERAPY FOR TREATING DISEASES OR CONDITIONS INDUCED BY CYCLOOXYGENASE-2 IN PATIENTS WITH RISK OF THROMBOTIC CARDIOVASCULAR EVENTS |
US20100009005A1 (en) * | 2005-05-24 | 2010-01-14 | Flamel Technologies ,S.A. | Novel acetysalicylic acid formulations |
US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
US20070043097A1 (en) * | 2005-07-18 | 2007-02-22 | Horizon Therapeutics, Inc. | Medicaments containing famotidine and ibuprofen and administration of same |
US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
WO2008027963A2 (en) * | 2006-08-31 | 2008-03-06 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
US9757529B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
CN104173359B (zh) * | 2014-09-05 | 2017-05-03 | 罗国安 | 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用 |
WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
US10272107B2 (en) * | 2017-09-05 | 2019-04-30 | Kenneth O. Russell | Method for treating inflammatory brain disorders and traumatic brain injury |
US10586872B2 (en) * | 2018-07-03 | 2020-03-10 | International Business Machines Corporation | Formation of wrap-around-contact to reduce contact resistivity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743596A (en) * | 1987-06-16 | 1988-05-10 | Lapin Alfred R | Anti-arthritic preparation |
CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
WO2001041761A2 (en) * | 1999-12-08 | 2001-06-14 | Pharmacia Corporation | Valdecoxib compositions |
GB0002336D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
WO2002017896A2 (en) * | 2000-08-29 | 2002-03-07 | Peter Van Patten | Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
-
2001
- 2001-10-11 GB GBGB0124459.9A patent/GB0124459D0/en not_active Ceased
-
2002
- 2002-10-10 NZ NZ532158A patent/NZ532158A/en unknown
- 2002-10-10 WO PCT/EP2002/011380 patent/WO2003033001A1/en not_active Application Discontinuation
- 2002-10-10 PL PL02369005A patent/PL369005A1/xx not_active Application Discontinuation
- 2002-10-10 US US10/487,759 patent/US20040235802A1/en not_active Abandoned
- 2002-10-10 EP EP02779476A patent/EP1435968A1/en not_active Withdrawn
- 2002-10-10 KR KR10-2004-7003586A patent/KR20040044891A/ko not_active Application Discontinuation
- 2002-10-10 CA CA002458981A patent/CA2458981A1/en not_active Abandoned
- 2002-10-10 BR BR0213181-1A patent/BR0213181A/pt not_active IP Right Cessation
- 2002-10-10 IL IL16062002A patent/IL160620A0/xx unknown
- 2002-10-10 JP JP2003535804A patent/JP2005505606A/ja active Pending
- 2002-10-10 RU RU2004114560/15A patent/RU2004114560A/ru not_active Application Discontinuation
- 2002-10-10 HU HU0401854A patent/HUP0401854A2/hu unknown
- 2002-10-10 MX MXPA04003365A patent/MXPA04003365A/es unknown
- 2002-10-10 CN CNA028200853A patent/CN1625405A/zh active Pending
-
2004
- 2004-02-18 ZA ZA200401302A patent/ZA200401302B/xx unknown
- 2004-04-05 NO NO20041432A patent/NO20041432L/no not_active Application Discontinuation
- 2004-04-15 CO CO04034535A patent/CO5570661A2/es not_active Application Discontinuation
-
2006
- 2006-12-08 AU AU2006249254A patent/AU2006249254A1/en not_active Abandoned
-
2007
- 2007-08-07 US US11/834,748 patent/US20080027032A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20040044891A (ko) | 2004-05-31 |
MXPA04003365A (es) | 2004-07-23 |
PL369005A1 (en) | 2005-04-18 |
CO5570661A2 (es) | 2005-10-31 |
AU2006249254A1 (en) | 2007-01-04 |
JP2005505606A (ja) | 2005-02-24 |
NO20041432L (no) | 2004-06-28 |
NO20041432D0 (no) | 2004-04-05 |
RU2004114560A (ru) | 2005-05-20 |
NZ532158A (en) | 2006-04-28 |
US20040235802A1 (en) | 2004-11-25 |
WO2003033001A1 (en) | 2003-04-24 |
US20080027032A1 (en) | 2008-01-31 |
EP1435968A1 (en) | 2004-07-14 |
IL160620A0 (en) | 2004-07-25 |
BR0213181A (pt) | 2004-08-31 |
CN1625405A (zh) | 2005-06-08 |
GB0124459D0 (en) | 2001-12-05 |
ZA200401302B (en) | 2005-01-04 |
CA2458981A1 (en) | 2003-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401854A2 (hu) | COX-2 inhibitorokat és aszpirint tartalmazó kombinációk | |
BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
DK1487541T3 (da) | Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme | |
NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
CY1110385T1 (el) | Χρηση αναστολεων της il-18 για τη θεραπεια και/ή προληψη της αθηροσκληρωσης | |
SE9802333D0 (sv) | Novel combination | |
SE9703693D0 (sv) | Novel combination | |
NO20005224D0 (no) | BTK inhibitorer og fremgangsmÕter for deres identifikasjon og anvendelse | |
DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
NO20024528L (no) | Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen | |
NO20052312L (no) | Kombinasjonsprodukt av inhibitor fra SRC-familien av ikke-reseptor-tyrosinkinaser og gemcitabin. | |
TR200502508T2 (tr) | IL-18 İnhibitörlerinin kullanımı. | |
DK1651234T3 (da) | Kombination af en mglur2-antagonist og ache-inhibitor til behandling af akutte og/eller kroniske neurologiske lidelser | |
SE0302488D0 (sv) | New combination | |
ATE266420T1 (de) | Kombinationspräparat, das selektive nmda nr2b- antagonisten und cox-2 inhibitoren enthält | |
DE60233436D1 (de) | In der mundhöhle dispergierbare feste pharmazeutische form | |
DK1233787T3 (da) | Produkt, der inhiberer signaltransduktion fra heterotrimere G-proteiner, kombineret med et andet cancerbekæmpende middel til terapeutisk anvendelse i cancerbehandlingen | |
DK1353948T3 (da) | Oplöselige biologiske analoge til bata-amyloidpeptid | |
EE05534B1 (et) | IL-18 inhibiitorite kasutamine ravimi valmistamiseks kardiomopaatia raviks ja/v?i ennetamiseks | |
SE0300445D0 (sv) | New combination | |
NO20033117L (no) | Farmasöytiske blandinger som inhiberer vaskul¶r proliferasjon og metoder for anvendelse derav | |
HUP0302738A2 (hu) | SARP-1 alkalmazása scleroderma kezelésére és megelőzésére | |
UY26218A1 (es) | Combinacion de inhibidores de mtp e inhibidores de hmg- coa reductasa y su uso en medicamentos. ley 17.164.- | |
HUP0301348A2 (hu) | COX-2 inhibitorokat tartalmazó fájdalomcsillapító és gyulladásgátló hatású készítmények és alkalmazásuk | |
IL139144A0 (en) | Mycobacterial inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |